Shares of Anika Therapeutics (ANIK) were up 4.62%, or $2.16, to $48.88 on a report from Zacks that analysts following the company are maintaining strong buy ratings on the company and have a one year consensus target price of $52.00 and predict it will earn 49 cents per share this quarter. Anika focuses on pain management, tissue regeneration and wound healing. Zacks Investment Research also has a buy rating and set a $55.00 target price on the stock in in February. A number of institutional investors have increased their holdings in Anika, including Victory Capital, Municipal Employees Retirement System of Michigan, Mason Street Advisors and Ladenburg Thalmann. Envestnet Asset Management purchased a new position in shares of Anika Therapeutics during the first quarter worth about $204,000.

Supernus Pharmaceuticals (SUPN) was down 1.2% to $33. Jefferies Group dropped its first quarter 2017 earnings per share Tuesday. Jefferies, however, has a buy rating and a $35.00 target price on the stock. Cantor Fitzgerald reaffirmed an overweight rating with a $34.00 price target Thursday. Also Thursday Cowen and Company reaffirmed an outperform rating and set a $40.00 price target, up previously from $33.00. On Tuesday Supernus reported net income for the first quarter of $10.3 million or $0.19 per diluted share as compared to net income of $4.8 million or $0.08 per diluted share in the first quarter of 2016.

Cytokinetics (CYTK) are up 1.06% to $14.35. The FDA has designated CK-2127107, a fast skeletal troponin activator, as an Orphan Drug for the treatment of spinal muscular atrophy. On Friday, May the company is scheduled to close a public offering of 5.26 million shares at $14.25 per share. Proceeds to Cytokinetics are expected to be to be approximately $75.0 million

More from Stocks

A Hungry Grizzly Bear Is Stalking the Stock Market

A Hungry Grizzly Bear Is Stalking the Stock Market

Tesla Has Lost 15% Since Musk's Take-Private Tweet

Tesla Has Lost 15% Since Musk's Take-Private Tweet

Why Most Americans Like a Volatile Stock Market: Study

Why Most Americans Like a Volatile Stock Market: Study

Should Retirees Invest in the Tech Sector?

Should Retirees Invest in the Tech Sector?

Here's How to Trade Walmart, Nordstrom, Macy's and J.C. Penney After Earnings

Here's How to Trade Walmart, Nordstrom, Macy's and J.C. Penney After Earnings